Pentanucleotide TTTTA repeat polymorphism of apolipoprotein(a) gene and plasma lipoprotein(a) are associated with ischemic and hemorrhagic stroke in Chinese: A multicenter case-control study in China

Stroke

Volumn 34, Issue 7, 2003, Pages 1617-1622

  Sun, Li ^a   Li, Zhaohui ^a   Zhang, Hongye ^a   Ma, Aiqun ^b   Liao, Yuhua ^c   Wang, Daowen ^c   Zhao, Bingrang ^d   Zhu, Zhiming ^e   Zhao, Jizong ^f   Zhang, Zhen ^a   Wang, Wei ^a   Hui, Rutai ^a  

^a FUWAI HOSPITAL   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d Tianjin Cardiovascular System Institute   (China)

^e THIRD MILITARY MEDICAL UNIVERSITY   (China)

^f Department of Neuroepidemiology   (China)

Author keywords

Apolipoproteins; Lipoproteins; Polymorphism; Stroke

Indexed keywords

ADENINE DERIVATIVE; APOLIPOPROTEIN A; THYMINE DERIVATIVE;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN VENTRICLE; CEREBRAL ATHEROTHROMBOSIS; CEREBROVASCULAR ACCIDENT; CHINESE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEL ELECTROPHORESIS; GENETIC POLYMORPHISM; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NUCLEOTIDE REPEAT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK; RISK FACTOR; STATISTICAL SIGNIFICANCE;

5' UNTRANSLATED REGIONS; ADULT; AGED; ALLELES; APOLIPOPROTEINS; APOPROTEIN(A); BRAIN ISCHEMIA; CASE-CONTROL STUDIES; CEREBRAL HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CHINA; COMORBIDITY; FEMALE; GENE FREQUENCY; HUMANS; LIPIDS; LIPOPROTEIN(A); LOGISTIC MODELS; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, GENETIC; RISK ASSESSMENT; RISK FACTORS;

EID: 0037477420     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000078370.12085.02     Document Type: Article

References (28)

1. World Health Statistics Annual, 1993. Geneva, Switzerland: World Health Organization; 1994.
2. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project: registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation. 1994;90:583-612.
3. Reed DM. The paradox of high risk of stroke in populations with low risk of coronary heart disease. Am J Epidemiol. 1990;131:579-588.
4. He J, Klag MJ, Wu L, Whelton PK. Stroke in the People's Republic of China, II: meta-analysis of hypertension and risk of stroke. Stroke. 1995;26:2222-2227.
5. Brazier L, Tiret L, Luc G, Arveiler D, Ruidavets JB, Evans A, Chapman J, Cambien F, Thillet J. Sequence polymorphisms in the apolipoprotein(a) gene and their association with lipoprotein(a) levels and myocardial infarction: the ECTIM Study. Atherosclerosis. 1999;144:323-333.
6. Zenker G, Koltringer P, Boné G, Niederkorn K, Pfeiffer K, Jürgens G. Lipoprotein(a) as a strong indicator for cerebrovascular disease. Stroke. 1986;17:942-945.
7. Jurgens G, Taddei-Peters WC, Koltringer P, Petek W, Chen Q, Greilberger J, Macomber PF, Butman BT, Stead AG, Ransom JH. Lipoprotein(a) serum concentration and apolipoprotein(a) phenotype correlate with severity and presence of ischemic cerebrovascular disease. Stroke. 1995;26:1841-1848.
8. Misirli H, Somay G, Ozbal N, Yasar Erenoglu N. Relation of lipid and lipoprotein(a) to ischaemic stroke. J Clin Neurosci. 2002;9:127-132.
9. Wityk RJ, Kittner SJ, Jenner JL, Hebel JR, Epstein A, Wozniak MA, Stolley PD, Stern BJ, Sloan MA, Price TR, et al. Lipoprotein(a) and the risk of ischemic stroke in young women. Atherosclerosis. 2000;150:389-396.
10. Alfthan G, Pekkanen J, Jauhiainen M, Pitkaniemi J, Karvonen M, Tuomilehto J, Salonen JT, Ehnholm C. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 1994;106:9-19.
11. Ridker PM, Stampfer MJ, Hennekens CH. Plasma concentration of lipoprotein(a) and the risk of future stroke. JAMA. 1995;273:1269-1273.
12. Glader CA, Stegmayr B, Boman J, Stenlund H, Weinehall L, Hallmans G, Dahlen GH. Chlamydia pneumoniae antibodies and high lipoprotein(a) levels do not predict ischemic cerebral infarctions: results from a nested case-control study in northern Sweden. Stroke. 1999;30:2013-2018.
13. Price JF, Lee AJ, Rumley A, Lowe GD, Fowkes FG. Lipoprotein(a) and development of intermittent claudication and major cardiovascular events in men and women: the Edinburgh Artery Study. Atherosclerosis. 2001;157:241-249.
14. Peng DQ, Zhao SP, Wang JL. Lipoprotein(a) and apolipoprotein E epsilon 4 as independent risk factors for ischemic stroke. J Cardiovasc Risk. 1999;6:1-6.
15. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1992;90:52-60.
16. Scholz M, Kraft HG, Lingenhel A, Delport R, Vorster EH, Bickeboller H, Utermann G. Genetic control of lipoprotein(a) concentrations is different in Africans and Caucasians. Eur J Hum Genet. 1999;7:169-178.
17. Sandholzer C, Hallman DM, Saha N, Sigurdsson G, Lackner C, Csaszar A, Boerwinkle E, Utermann G. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet. 1991;86:607-614.
18. Ogorelkova M, Kraft HG, Ehnholm C, Utermann G. Single nucleotide polymorphisms in exons of the apo(a) kringles IV types 6 to 10 domain affect Lp(a) plasma concentrations and have different patterns in Africans and Caucasians. Hum Mol Genet. 2001;10:815-824.
19. Trommsdorff M, Kochl S, Lingenhel A, Kronenberg F, Delport R, Vermaak H, Lemming L, Klausen IC, Faergeman O, Utermann G, et al. A pentanucleotide repeat polymorphism in the 5′ control region of the apolipoprotein(a) gene is associated with lipoprotein(a) plasma concentrations in Caucasians. J Clin Invest. 1995;96:150-157.
20. Kalina A, Csaszar A, Fust G, Nagy B, Szalai C, Karadi I, Duba J, Prohaszka Z, Horvath L, Dieplinger H. The association of serum lipoprotein(a) levels, apolipoprotein(a) size and (TTTTA)(n) polymorphism with coronary heart disease. Clin Chim Acta. 2001;309:45-51.
21. Amemiya H, Arinami T, Kikuchi S, Yamakawa-Kobayashi K, Li L, Fujiwara H, Hiroe M, Marumo F, Hamaguchi H. Apolipoprotein(a) and pentanucleotide repeat polymorphisms are associated with the degree of atherosclerosis in coronary heart disease. Atherosclerosis. 1996;123:181-191.
22. Warnick GR, Knopp RH, Fitzpatrick V, Branson L. Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cut-points. Clin Chem. 1990;36:15-19.
23. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
24. Cardon LR, Bell JI. Association study designs for complex diseases. Nat Rev Genet. 2001;2:91-99.
25. Kronenberg F, Kronenberg MF, Kiechl S, Trenkwalder E, Santer P, Oberhollenzer F, Egger G, Utermann G, Willeit J. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation. 1999;100:1154-1160.
26. Ichikawa T, Unoki H, Sun H, Shimoyamada H, Marcovina S, Shikama H, Watanabe T, Fan J. Lipoprotein(a) promotes smooth muscle cell proliferation and dedifferentiation in atherosclerotic lesions of human apo(a) transgenic rabbits. Am J Pathol. 2002;160:227-236.
27. Byrne DJ, Jagroop IA, Montgomery HE, Thomas M, Mikhailidis DP, Milton NG, Winder AF. Lipoprotein(a) does not participate in the early acute phase response to training or extreme physical activity and is unlikely to enhance any associated immediate cardiovascular risk. J Clin Pathol. 2002;55:280-285.
28. Kargman DE, Tuck C, Berglund L, Lin IF, Mukherjee RS, Thompson EV, Jones J, Boden-Albala B, Paik MC, Sacco RL. Lipid and lipoprotein levels remain stable in acute ischemic stroke: the Northern Manhattan Stroke Study. Atherosclerosis. 1998;139:391-399.